Halifax, Nova Scotia, October 11th, 2018 – Sona Nanotech Inc. (CSE: SONA) today announced the signing of an agreement with global biotech company Expedeon Ltd. (ETR: EXN) for the supply of Sona’s unique gold nanorods for integration into Expedeon’s product range.
Expedeon is a global provider of innovative technologies and services for the life sciences and diagnostics industries. Following evaluation of the quality and sensitivity of Sona’s gold nanorods, Expedeon decided to include their Gemini and Omni products within their complete range of gold nanoparticles and conjugation technologies.
Under the terms of the agreement, signed Oct 3rd, 2018, Expedeon has exclusive rights to promote and market the nanorods to life science researchers and diagnostic companies around the world via its extensive distribution network and strong direct sales channels.
The company will invest in R&D to incorporate Sona’s technology into its comprehensive product range coupled with its own proprietary technologies. Both companies are exploring how they can develop the partnership even further to increase the offerings to their customers.
Sona Nanotech CEO Darren Rowles said: “Expedeon has a built a reputation as a world-leading business in the life sciences and diagnostics industries and is considered the go-to company for innovative reagents. We are delighted to have signed this agreement with Expedeon, which will open access to new markets, new technologies and new lateral flow test developers for Sona to collaborate with and develop next-generation lateral flow assays. To have our products integrated into the Expedeon product line is a huge milestone for Sona as we continue to work towards our goal of becoming a global life sciences brand.”
Expedeon CEO Heikki Lanckriet said: “We are excited to be incorporating Sona’s technologies into our range of gold nanoparticle technologies. We were really impressed by the quality and sensitivity of their gold nanorods. We believe many of our customers are going to be interested in this innovative technology and the multiplex capabilities, and we are eager to be expanding our offering to new markets.”
About Sona Nanotech Inc.
Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the research and development of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market.
Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.
Sona is a publicly listed company on the Canadian Securities Exchange existing under the laws of Nova Scotia, with its operations in Nova Scotia.
Expedeon is an enabler of exciting advances in medical science and patient care. The Company’s core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon’s technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers’ development and commercialisation objectives. Expedeon’s products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Australia Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03) Revenues have grown from €1.8m in 2016 to expected revenues of €13-14m in 2018.
For More Information
For more information about Sona, please contact:
President and Chief Executive Officer
Telephone: (902) 442-7192
Email: Darren Rowles firstname.lastname@example.org
Neither Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accept responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to the Amalgamation (including the structure of the Amalgamation), the Amalgamation (including shareholder approval, shareholder support, and other terms), the Private Placement (including its completion and the use of proceeds from the Private Placement), the directors and management of the resulting issuer upon completion of the Amalgamation, and the implementation of Sona’s business plan. Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the completion of the Amalgamation and matters relating thereto; and risks associated with the marketing and sale of securities, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company’s common share price and volume. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.
There are a number of important factors that could cause the Company’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others, risks related to Sona’s proposed business, such as failure of the business strategy and government regulation; risks related to Sona’s operations, such as additional financing requirements and access to capital, reliance on key and qualified personnel, insurance, competition, intellectual property and reliable supply chains; risks related to Sona and its business generally, such as infringement of intellectual property rights and conflicts of interest. The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. While the Company may elect to, it does not undertake to update this information at any particular time.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS
BioNova, the association for Nova Scotia’s life sciences industry, has released its plan to at least double the biotech sector in the next 12 years, creating 2,700 jobs with average salaries of more than $100,000.
Titled BioFuture 2030, the report outlines a plan to increase the number and size of life sciences companies, with the goal of increasing jobs, investment and research. Penned by BioNova staff with the aid of a 10-member advisory group, the report was released Wednesday at a ceremony in Halifax attended by government and industry leaders.
It stresses that the life science sector now constitutes a $9 trillion industry worldwide, which provides a huge opportunity for Nova Scotia. The province so far has grown its industry strongly and should take concrete steps to ensure that it continues to capitalize on this booming industry, says the report.
“BioFuture 2030 allows us to see what is possible,” said BioNova chair Kevin Sullivan in the introduction of the report. “This strategy sets some ambitious goals that will benefit our sector, our community, and move our economy into a prosperous future.”
The report says Nova Scotia has already established a health and life sciences cluster comprising more than 100 companies with total annual revenues of more than $300 million. These companies directly employ more than 1,500 people, earning an average salary of about $61,000 a year – almost $25,000 more than the provincial average.
With an underlying theme of collaboration among industry, government and academia, the BioFuture 2030 report outlines a series of goals the industry hopes to attain by 2030. It also sets out five projects that will help to reach these goals, which are:
- Double the number of health and life sciences companies to 200.
- Almost triple the number of employees at these companies to 4,200.
- Increase the average annual income to $102,000 per employee.
- And almost quadruple annual sales for the sector to $1.1 billion.
The first project to help reach these goals will be to improve business development tools so companies grow more quickly. The biotech community plans to support and improve the best organizations and programs that help companies to grow. It also aims to identify and alleviate gaps in the programing.
Second, BioNova and its partners hope to attract more talent by improving their network and database of life sciences professionals. They also plan to promote Nova Scotia as a place for these professionals, and institute training programs to develop more talent.
Third, the community plans to develop the ecosystem by enhancing links between research institutions and industry. It is proposing the creation of industry-institution liaison groups, and chief innovation officers at key institutions and within government.
The fourth project involves communications and marketing. The community wants to broadcast the benefits of a strong life sciences industry to Nova Scotians, and use the same messaging to attract talent and capital to the province.
Finally, BioNova plans to establish a hub for life sciences sales and business development. It will create a life sciences-focused sales training program and create an understanding within the industry of what it means to be globally competitive.
“We have the right ingredients, the talent and resources needed to grow our sector, develop products that will change the world, and transform Nova Scotia’s economy,” said BioNova managing director Scott Moffit in a statement. “BioFuture 2030 is the recipe that pulls it all together.”
NEWS RELEASE: October 10, 2018 – Halifax, NOVA SCOTIA – Today BioNova released BioFuture 2030, the first industry-led economic strategy to grow Nova Scotia’s health and life sciences sector. BioFuture 2030 leverages the expertise and resources within the sector to deliver the tools entrepreneurs need to commercialize life-changing research, attract investments, create jobs, access new markets and improve the quality of life of Nova Scotians.
“The comprehensive strategic plan, BioFuture 2030, is a call to action for all Nova Scotian life sciences organizations,” said Andy Fillmore, Parliamentary Secretary to the Minister of Canadian Heritage and Multiculturalism and Member of Parliament for Halifax, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA). “Taking a sector-wide approach and sharing best practices will speed up and spread out the adoption of innovations and leverage new ideas in world-class health products for commercialization, making the sector stronger as a whole.”
The Government of Canada, through ACOA, is providing a $495,000 contribution to BioNova to further the development, growth and support of health and life sciences companies. The non-repayable investment, provided through ACOA’s Business Development Program, builds on the commitments made by the Government of Canada and the four Atlantic Provinces to drive economic growth through the Atlantic Growth Strategy by making strategic investments in initiatives that build on the region’s competitive advantages, such as its strong export potential, growing innovation ecosystem, and skilled workforce.
“Our CEOs see health and life sciences as a driver of economic growth,” said Scott Moffitt, Executive Director of BioNova. “This is our action plan to compete for a piece of the $9 trillion global health and life sciences economy.”
BioFuture 2030 is the result of over 50 in-depth interviews and numerous collaborations between CEOs and industry leaders across Nova Scotia. These sector champions shared their ideas on how making the health and life sciences industry a priority would deliver economic and health benefits to Nova Scotians and Canadians, as well as prepare companies for success on the world stage.
The vision of BioFuture 2030 is to achieve a connected and collaborative Health and Life Sciences community that reaches its full potential. The plan sets out a clear path for implementation and will be led by five action teams that will focus on making connections, recruiting talent, improving public policies, unifying the sector’s value proposition and building a sales culture.
“We have the right ingredients, the talent and resources needed to grow our sector, develop products that will change the world and transform Nova Scotia’s economy. BioFuture 2030 is the recipe that pulls it all together,” continued Mr. Moffitt.
Hosted at the Life Sciences Research Institute, the launch was attended by over 50 health and life science industry leaders. Members of government and Industry leaders were there to present the plan including Andy Fillmore, Member of Parliament for Halifax, Jeffrey Mullen, Director of Enterprise Development, Atlantic Canada Opportunities Agency, Brian Lowe, Vice Chair of BioNova, and Peter Hickey, CEO of Adaptiiv Inc.
BioNova leads, accelerates, and advocates for Nova Scotia’s growing health and life sciences sector. Since 1993, BioNova has been accelerating the growth of its member companies. By hosting networking and educational events, and providing connections to potential funders and business resources, BioNova helps companies succeed. While these companies commercialize life-changing research to improve healthcare, provide healthier food, and develop sustainable solutions, BioNova advocates on behalf of the sector. BioNova champions the sector’s cluster of world-class research facilities, incubator programs, and companies who, together, bring investment and jobs to Nova Scotia.
For further information, media may contact:
Marketing Manager, BioNova
Halifax-based company Sona Nanotech is manufacturing the first ever toxin-free gold nanorods that are safe for researchers to use in human trials to treat numerous diseases. The company, which began as a research project, is now working towards commercializing their innovative products while building key partnerships with distributors.
A gold nanorod is a microscopic rod-shaped particle that can be used in lateral flow assays, such as pregnancy tests, as well as to deliver medicine to specific areas of the body that require treatment. Gold nanorods have many applications in healthcare including cancer treatment, liposuction, diagnostic imaging and location-specific drug and pain treatment. Before Sona’s toxin-free gold nanorods, scientists would try to mitigate toxin exposure by coating the nanorods, rather than reconstruct them altogether.
Since Sona’s breakthrough, the company has been busy working to bring their gold nanorods to the global market. The recently appointed President and CEO, Darren Rowles, has over 15 years of experience working with gold nanoparticles and has been leading the company’s business development efforts. Sona recently announced a merger with Stockport Exploration, a move that has allowed them to focus solely on producing gold nanorods. They also received a funding boost from Atlantic Canada Opportunities Agency (ACOA), giving them the opportunity to focus on their global ambitions and build a quality team.
Halifax-based company Adaptiiv, formerly known as 3D Bolus, is using advanced software to create personalized 3D-printing medical devices to help cancer patients receive more precise radiation treatments and improve their quality of care. Adaptiiv’s customized medical devices have been well received by clinicians, with sales in six countries worldwide.
One of Adaptiiv’s most revolutionary medical devices is their 3D-printed bolus. To improve the accuracy of radiation treatment, a tissue-like material called a bolus is applied to the patient’s body. Unlike traditional boluses, Adaptiiv’s advanced software allows clinicians to design 3D-printed boluses using data from the patient’s CT scans to create a personalized design, improving the patient experience. The boluses are cost effective and fit the contours of the patient, which allows for more accurate dosages in the areas that need it most and sparing healthy tissue during radiation therapy.
Aside from improving the lives of cancer patients, Adaptiiv also provides high-quality jobs to Atlantic Canadians, stimulating the economy. With recent funding from Atlantic Canada Opportunities Agency (ACOA) and recently receiving FDA (510K) approval, Adaptiiv has big plans to upgrade their marketing strategy and bring their patient-specific solution to the global radiotherapy market.
Spring Loaded Technology is one of many made-in-Nova Scotia companies with an innovative health technology that could cut costs and improve healthcare for the province but has yet to be formally covered through Nova Scotia’s healthcare. Guided by the input of hundreds of physiotherapists, orthopedic surgeons, and orthotists, the company was able to launch Levitation – the world’s first compact and powerful bionic knee brace – last year to a global market.
The Levitation knee brace uses liquid spring technology to store energy when the knee is bent and release it when the knee is straightened. For the wearer, the brace reduces the pressure on the knee, enhances stability, and prevents further damage to the joint.
“We’ve seen our product help patients in a wide variety of ways, including reducing pain, restoring strength and mobility, retaining independence and dignity, and even delaying or avoiding the need for surgery,” said Chris Cowper-Smith, CEO of Spring Loaded Technology.
A global preference for non-invasive treatments has been driving Spring Loaded’s sales across North America. The company has seen its market broaden from helping athletes recover from injuries to helping people with mobility issues, especially those living with osteoarthritis.
According to the Arthritis Society of Canada, osteoarthritis is a degenerative health issue affecting nearly five million Canadians. One of the most difficult challenges for those living with osteoarthritis is to remain active, to slow the degenerative process.
Spring Loaded has met this challenge by adapting the Levitation knee brace specifically for patients living with osteoarthritis. So now, the brace not only reduces pain and pressure across the whole knee, it also provides better support and alignment so that people can get back to being active.
Additionally, the Levitation knee brace allows people to buy time before needing surgery and may even prevent it altogether, as Jane Grover, a grandmother with osteoarthritis, can attest. Grover explains in a Spring Loaded corporate video that when she found out she needed a knee replacement surgery; she opted for a Levitation knee brace instead. Today she continues to enjoy an active lifestyle that includes keeping up with her grandchildren.
“The last thing I wanted was more surgery. I was going to try out one of the braces that Spring Loaded Technology makes because we have experience with my granddaughter having it. (She) was diagnosed with muscular dystrophy and they’ve just been a miracle for her. I went and I got one and I already feel 20 years younger, and I really, really feel hopeful that I don’t have to go through the surgery for a long time,” said Grover.
Meanwhile, the number of Nova Scotians needing orthopedic surgeries is on the rise. Last year the Canadian Institute for Health Information released its annual report on wait times showing that Nova Scotians needing hip or knee replacements have the longest average wait time for patients in Canada.
The wait time crisis has been ongoing for years. In 2016 alone, over $8 million was invested in orthopedic surgeries in the province in an attempt to shorten the wait list.
Offering the Levitation knee brace in Nova Scotia could potentially have a large economic and health impact for the province, reducing future orthopedic surgery wait times.
“Our braces are enabling people to be more physically active, productive, and lead healthier lives than they could otherwise. The province should seriously consider a range of more costeffective solutions for treating knee pain and mobility impairments,” said Cowper-Smith.
In June of this year Spring Loaded Technology was awarded Nova Scotia’s 2018 Exporter of the Year award. This came on the coattails of a funding boost they received from Atlantic Canada Opportunity’s Agency to support their plans to expand their manufacturing capacity to keep up with demand and use customer relationship management and enterprise resource planning software to expand their reach.
Headquartered in Dartmouth, Nova Scotia, Spring Loaded Technology employs 30 people full time and plan to hire more as production increases. Spring Loaded Technology is proof of the success that can come from investing in life science, whether it is to create jobs, strengthen the economy, or change lives.
Like most provinces in Canada, Nova Scotia spends about 40 per cent of its budget on health care. This year the provincial health department’s budget is $4.37 billion(1) . That’s over $1 million a day.
Yet our health care system is ailing with overcrowded emergency rooms, lengthy wait times, and over 50,000(2). Nova Scotians on a provincial list looking for a family doctor.
As our population ages, health care costs are projected to grow well beyond sustainable levels. So what can be done to improve a situation that has, at times, been called a “crisis” by patients and clinicians?
Nova Scotia’s Health Minister Randy Delorey said recently, in an interview with The Star Halifax, “… better health care is not always defined by throwing more money at it. You need to make sure that where you are investing the money are the right areas that are going to provide results.”
Healthcare Solutions 2020 – Health Care Innovation Project
Rather than attempting to manage an unsustainable health care system by cutting spending, BioNova – Nova Scotia’s health and life sciences association – is proposing a different approach to support the system; one that facilitates the adoption of new medical technologies. Working in partnership with MEDEC, the association of Canadian medical technology companies, BioNova is spearheading Healthcare Solutions 2020, a health care innovation project for Atlantic Canada. The project is led by a committee of Canadian health care innovators from both industry and government.
Paul Bradley is managing the health care innovation project. As a former vice president of strategic affairs at Johnson & Johnson Medical Products and the past chair of MEDEC, he is pleased to have assembled such an accomplished and diverse committee. “Having committee members who are embedded in our health care system and those representing the private sector brings a unique blend of perspectives,” says Bradley.
This committee will map out an approach to empower the region’s health care system to adopt new medical technologies and transform it into an economic driver. “Adopting made-in-Nova-Scotia innovations has the potential to both increase the quality of our health care and manage our costs,” says Scott Moffitt, Managing Director of BioNova.
Potential of Our Health and Life Sciences Sector
As a sector, health is a booming industry world-wide. The Canadian Venture Capital & Private Equity Association recently posted that Nova Scotia’s investment scene is also heating up, attracting $38 million in venture capital in the first quarter of 2018.
Nova Scotia’s world-class research facilities and incubator programs are already galvanizing a cluster of health and life science companies. Unfortunately, as long as the health care system is seen as a cost, and as Paul Bradley, Healthcare Solutions 2020 Project Manager long as administrators fail to be early adopters of home-grown innovation, this region will fail to realize the economic potential of the global health revolution.
Barriers to Adoption of Innovation
There are multiple barriers affecting the adoption of new medical technologies into Canada’s 13 individual provincial and territorial health care systems, from siloed budgets among hospitals and home care services to a procurement process that is price-based.
When it comes to the adoption of new medical technologies, Paul Bradly sees a broader, value-based process as the way forward. He describes a scenario of a company developing a new computer navigation technology for surgery that would enable the surgeon to use minimally invasive incisions. “It may mean spending more of the operating room’s budget, but with fewer days in hospital and a shorter rehab, the savings are significant,” he says. “Yet, because the hospital’s budget is separate from the home care budget, it makes it tough to reconcile the value delivered by the new technology.”
Yet, procurement is only one piece of the puzzle. Private sector innovation often enters the health care system through government funded pilot projects. Unfortunately, once companies emerge from these pilot programs they often face the commercialization valley of death. Even if the pilot has a good outcome, there is no clear process to scale it and bring the new technology to market. This approach is not serving our health care system well.
Moving Towards Value-Based Health Care
To strengthen Nova Scotia’s health and life science sector there needs to be stronger links between the research performed here, the companies that start here, and the public system that provides the majority of health services. “When companies move beyond the pilot stage, not only does it have a positive impact on the economy, but patients gain access to breakthrough technologies that improve their quality of life,” says Bradley.
The Healthcare Solutions 2020 committee envisions a value-based health care system that breaks down the budget silos and improves data collection so product or service performance is tied to patient outcomes. The committee is also reviewing what other jurisdictions have done to support the adoption of health care innovation, including:
̵ creating a single point of entry for companies to pitch their technology,
̵ establishing the position of a Chief Health Innovation Strategist, a role that would facilitate connections between health care buyers and innovative vendors, and
̵ developing policies that support industry taking the lead in developing innovative solutions to defined public health problems.
“Our purpose is to create a roadmap that supports innovation adoption and better recognizes total benefits to health care,” says Bradley.
Health Care Can Be an Economic Driver
Healthcare Solutions 2020 is about economic growth as well. By establishing a system that encourages local innovation adoption, startup companies gain access to clinical users, engage and learn from a first customer and receive international validation when the companies home jurisdiction adopts the technology – all of this is in addition to helping the healthcare system. “It’s going to take all of us working together to build a health system that works and that is sustainable into the future,” says Moffitt.
1 Nova Scotia Department of Health and Wellness budget 2018-2019
2 Nova Scotians on a provincial list looking for a family doctor. http://www.nshealth.ca/need-family-practice-data
Halifax, Nova Scotia, October 3, 2018 – Sona Nanotech Inc. (CSE: SONA) (“Sona” or the “Company”) is pleased to announce that the Canadian Securities Exchange (CSE) has approved the Company’s application to list its common shares on the CSE. Effective October 4, 2018, the Company’s shares will commence trading on the CSE under the symbol “SONA”.
Overview of Sona
Sona is a nano technology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the research and development of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market.
Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nano technologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.
Pursuant to the terms of an Amalgamation, every four (4) common shares of Stockport Exploration Inc. were exchanged for one (1) common share of Sona Nanotech Ltd. (the “Sona Shares”); and every 1.5802 common shares of Sona Nanotech Ltd. were exchanged for one (1) Sona Share. The amalgamation was completed on August 8, 2018.
Stockport Exploration Inc. voluntarily delisted its common shares from the TSX Venture Exchange on August 7, 2018, and filed an application for listing its common shares on the CSE.
For More Information
For more information about Sona, please contact:
Athletigen teams up with CrossFit leader MobilityWOD
HALIFAX – September 17, 2018 – Athletigen Technologies, Inc. has announced the launch of its Optimum Movement and Recovery report, a DNA product that was created in partnership with Dr. Kelly Starrett and his company MobilityWOD.
The report uses 23andMe, AncestryDNA, or Athletigen DNA data, for more than 70 genetic markers to deliver 25 fundamental insights into injury risk, exercise recovery, and sleep hygiene. Customers who have already had their DNA sequenced can now use the Optimum Movement and Recovery report to gain additional knowledge about their bodies. Alternatively, if customers need a DNA kit to start their genetic journey, they can purchase one directly from Athletigen.
“It’s exciting to see people use their DNA to explore the depths of their unique human technology. Working together with Dr. Kelly and Juliet Starrett to deliver a solution that helps people make informed decisions for optimal performance and informed living has been pure joy,” says Athletigen CEO Dr. Jeremy Koenig. “It is an honour to work side by side with people who are experts in their craft and who are driven to help humans perform, feel, and live better. We want to continue to help people make decisions based on their individual bodies. This kind of interdisciplinary collaboration is essential to make this a reality for all humans.”
The Optimum Movement and Recovery report, while non-diagnostic, helps customers understand the impact of DNA on traits such as tendon and ligament injury risk, post-exercise soreness and inflammation, and sleep quality. Understanding our DNA foundation can be empowering, giving every person the ability to take charge of their health. Every person’s DNA is 99.5% the same. By understanding the 0.5% that makes each person unique, as well as the environmental factors that combine with DNA to influence athletic performance and recovery, people can make more informed lifestyle decisions daily.
MobilityWOD was founded in 2005 by Dr. Kelly Starrett and Juliet Starrett with the goal of becoming the ultimate guide to eliminating pain, preventing injury and maximizing athletic performance. MobilityWOD has grown into a leader in the CrossFit industry and has worked with high-profile clients such as the New Zealand All Blacks, UFC fighter Georges St. Pierre, actor Jason Statham, and author Tim Ferriss.
“Genetics and understanding the implication of modern genetics on my person is here to stay. It’s going to be part of the conversation,” said MobilityWOD founder Kelly Starrett. “The problem is that trying to sort through and make sense of this incredible technology is difficult, at best. So we have partnered with our friends at Athletigen to take your DNA data and translate it into actionable steps and real behaviors that can improve your life.”
Athletigen is funded by private equity investors, the Government of Canada through repayable loans from the Atlantic Canada Opportunities Agency, and the province of Nova Scotia through Nova Scotia Business Inc.
—- 30 —-
Click here for a sample version of the Optimum Movement and Recovery DNA report.
Athletigen is a company founded on the same performance principles that are used to help the most elite athletes in the world achieve greatness. We are driven to empower all people to understand their DNA and reach their full potential. Our mission is to help people connect their DNA data to products and services that are specific to their personal needs and are aligned with a healthful life. We achieve this through adhering to the highest scientific standards, a commitment to education, and strategic alignment with partners who embrace our passion for performance. We believe that everyone is Made for More™.
About Athletigen’s Optimum Movement and Recovery Report
The new Optimum Movement and Recovery DNA report from Athletigen and MobilityWOD unlocks the power of raw DNA data files provided to every 23andMe and AncestryDNA customer with over 25 insights into injury risk, exercise recovery, and sleep hygiene. These traits include:
- Tendon and ligament injury risk
- Hamstring injury risk
- Shoulder dislocation
- Fracture risk and bone mineral density
- Age-related strength loss
- Post-exercise soreness and inflammation
- Post-exercise recovery time
- Soft tissue recovery
- Sleep quality
About Dr. Jeremy Koenig
Dr. Jeremy Koenig, Athletigen CEO and Founder, has a background in commercializing genetic information into practical applications. Dr. Koenig was a varsity track-and-field athlete during the completion of his Ph.D. in Biochemistry and Molecular Biology at Dalhousie University in Halifax, Nova Scotia, Canada. Following graduate school, Dr. Koenig pursued postdoctoral training in human microbiome and genetics research at Cornell University. He was a Professor of Nutrigenomics, before moving to the biomedical industry to work on developing and commercializing a genetics-based fertility test. He founded Athletigen in 2014 to accelerate scientific discovery through the delivery and application of DNA to every human.
Athletigen Technologies Inc.,
211 Horseshoe Lake Drive,
Appili Therapeutics, a Halifax-based drug development company, has appointed its first ever Chief Scientific Officer.
Armand Balboni, the new CSO, will be responsible for the company’s clinical and scientific strategy as well as steering its programs through regulatory and pre-commercialization processes.
“Armand’s medical science, business, and military experience, including his particular focus in infectious disease, is a powerful combination, and having an expert of his caliber on our team is a ‘win’ for this company and our shareholders,” said Appili CEO Kevin Sullivan in a statement.
Balboni has over 20 years of medical and drug development experience across an extensive range of civilian and military organizations.
Early in his career, Balboni completed a period of active duty with the U.S. Army as the Deputy Director of its Office of Regulated Activities and was a senior reviewer on the clinical pharmacovigilance team. He is also a partner, senior advisor and member of the Board of Directors of the investment advisory firm Bloom Burton & Co.
“Appili is doing very important work in the infectious disease space, from developing options for some of the most threatening drug-resistant bacteria emerging in our healthcare landscape, to tackling head-on significant bioterrorism threats,” Balboni said in a statement.
In January, Appili struck a deal with the National Research Council of Canada to work on a vaccine that could protect people against a potential bioterror threat. The vaccine, called ATI-1701, will protect against bacteria called Francisella tularensis.
The company, which is considering a listing on the Toronto Stock Exchange, has raised a total of $11.8 million in less than two years. The company is now on a fast-track to get its portfolio of anti-infectious drug candidates to market within the next couple of years.
Already, Appili has had positive results from its first clinical trial in Canada and the US for its ATI-1501 drug compound.
Said Balboni: “I have been impressed with their notable progress in the three years that the company has been operating, and am eager to continue supporting their efforts as the first Chief Scientific Officer.”